Skip to content

Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)210-219
Number of pages10
JournalBritish Journal of Cancer
Volume117
Issue number2
DOIs
DateAccepted/In press - 22 May 2017
DatePublished (current) - 11 Jul 2017

Abstract

BACKGROUND: Complete tumour response (pCR) to neo-adjuvant chemo-radiotherapy for rectal cancer is associated with a reduction in local recurrence and improved disease-free and overall survival, but is achieved in only 20-30% of patients. Drug repurposing for anti-cancer treatments is gaining momentum, but the potential of such drugs as adjuncts, to increase tumour response to chemo-radiotherapy in rectal cancer, is only just beginning to be recognised.

METHODS: A systematic literature search was conducted and all studies investigating the use of drugs to enhance response to neo-adjuvant radiation in rectal cancer were included. 2137 studies were identified and following review 12 studies were extracted for full text review, 9 studies were included in the final analysis.

RESULTS: The use of statins or aspirin during neo-adjuvant therapy was associated with a significantly higher rate of tumour downstaging. Statins were identified as a significant predictor of pCR and aspirin users had a greater 5-year progression-free survival and overall survival. Metformin use was associated with a significantly higher overall and disease-free survival, in a subset of diabetic patients.

CONCLUSIONS: Aspirin, metformin and statins are associated with increased downstaging of rectal tumours and thus may have a role as adjuncts to neoadjuvant treatment, highlighting a clear need for prospective randomised controlled trials to determine their true impact on tumour response and overall survival.

    Research areas

  • Aspirin, Chemotherapy, Adjuvant, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Metformin, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Radiation Tolerance, Rectal Neoplasms, Risk Factors, Journal Article, Meta-Analysis

Documents

DOI

View research connections

Related faculties, schools or groups